title: Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
abstract: OBJECTIVE
  The purpose of this study is to update the guidelines for antiemetic therapy to be used with anticancer agents of low to minimal emetic potential.
  
  
  METHODS
  Experts from the Multinational Association of Supportive Care in Cancer (MASCC) met in Perugia in 2009 to revise the MASCC antiemetic consensus guidelines. There is an increasing number of anticancer agents which are classified as being associated with a low or minimal risk of nausea and vomiting. However, the emetic potential of such agents and particularly those given as prolonged oral therapy is not well documented, and neither is the optimal antiemetic therapy.
  
  
  RESULTS
  The consensus is that patients receiving anticancer therapy of low emetic potential should receive single-agent antiemetic prophylaxis such as dexamethasone, 5 hydroxytryptamine3 (5HT3) receptor antagonists, or dopamine receptor antagonists. Those receiving anticancer therapy of minimal emetic potential and who have no prior history of nausea and vomiting should not receive antiemetic prophylaxis. Those who experience nausea and vomiting subsequently can receive single-agent dexamethasone, 5HT3 receptor antagonists, or dopamine receptor antagonists.
  
  
  CONCLUSIONS
  More data are needed on the emetic potential and the outcome of antiemetic treatment with agents likely to fall into the low or minimal emetic potential category.
authors.affiliation: Cancer Council Australia, GPO Box 4708, Sydney, NSW, Australia 2001. ian.olver@cancer.org.au
authors.forename: Ian
authors.initials: I
authors.lastname: Olver
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Clark-Snow
authors.forename: Enzo
authors.initials: E
authors.lastname: Ballatori
authors.forename: Birgitte T
authors.initials: BT
authors.lastname: Espersen
authors.forename: Emilio
authors.initials: E
authors.lastname: Bria
authors.forename: Karin
authors.initials: K
authors.lastname: Jordan
mesh_terms: D000932:Antiemetics / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage; D018492:Dopamine Antagonists / Q000008:administration & dosage; D006801:Humans; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control*; D064729:Neurokinin-1 Receptor Antagonists; D017410:Practice Guidelines as Topic; D012702:Serotonin Antagonists / Q000008:administration & dosage; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D018492:Dopamine Antagonists; D064729:Neurokinin-1 Receptor Antagonists; D012702:Serotonin Antagonists; D003907:Dexamethasone
references.citation: Oncologist. 2007 Sep;12(9):1143-50
references.pmid: 17914084
references.citation: N Engl J Med. 1981 Oct 15;305(16):905-9
references.pmid: 7024807
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2932-47
references.pmid: 16717289
references.citation: Support Care Cancer. 2005 Jul;13(7):529-34
references.pmid: 15700131
references.citation: J Clin Oncol. 2000 Oct 1;18(19):3409-22
references.pmid: 11013282
references.citation: Support Care Cancer. 2005 Feb;13(2):109-11
references.pmid: 15714358
references.citation: Ann Oncol. 1998 Jul;9(7):759-65
references.pmid: 9739443
references.citation: Tumori. 2001 Nov-Dec;87(6):379-82
references.pmid: 11989589
references.citation: Clin Invest Med. 1986 Nov;9(4):225-31
references.pmid: 3542325
references.citation: Drugs. 1983 Feb;25 Suppl 1:63-73
references.pmid: 6682376
references.citation: Support Care Cancer. 2006 Dec;14(12):1262-5
references.pmid: 16896880
references.citation: BMJ. 2001 Jul 7;323(7303):16-21
references.pmid: 11440936
references.citation: J Clin Oncol. 1997 Jan;15(1):103-9
references.pmid: 8996130
references.citation: N Engl J Med. 2008 Jun 5;358(23):2482-94
references.pmid: 18525044
references.citation: J Clin Oncol. 2004 Feb 15;22(4):725-9
references.pmid: 14966097
references.citation: Support Care Cancer. 2005 Feb;13(2):80-4
references.pmid: 15599601
references.citation: J Clin Oncol. 1984 Jun;2(6):691-5
references.pmid: 6374058
references.citation: Support Care Cancer. 2004 Jun;12(6):446-53
references.pmid: 15045572
references.citation: Rev Recent Clin Trials. 2006 Jan;1(1):61-6
references.pmid: 18393781